Myeloproliferative Neoplasm Drugs Market Consumer Trend Analysis 2020 Sales Strategy, Industry Landscape, Global Significant Growth, Size, Share, Business Opportunities, Gross Margin, Comprehensive Research To 2027
Myeloproliferative Neoplasms (MPNs) are a group of rare disease, in which the bone marrow produces excess blood cells. It can be white blood cells, red blood cells or platelets. The overproduction of blood cells by the bone marrow creates hindrance in the smooth flow of blood, which leads to various symptoms such as progressive cytopenias, cachexia, and weight loss, splenomegaly, and blastic transformation. These conditions are developed gradually over a period of time.
Get Sample PDF Brochure with Impact of COVID19: https://www.coherentmarketinsights.com/insight/request-sample/930
Most people are diagnosed after the age of 60 years, when they were accompanied by many other health issues, makes the treatment more difficult. The major symptoms associated with MPNs include bleeding problem, anemia, chest pain, fatigue, enlarged spleen, and weight loss. According to Annals of Hematology, approximately 90% of patients has experienced MPN-symptoms in past 12 months, wherein women are reported to have higher overall burden than men. The treatment for myeloproliferative neoplasms is mainly aimed to reduce the excess number of blood cells circulation. The concept of myleoproliferative disease was first given by hematologist Williom Dameshek in 1950. However, in 2008, World Health Organization (WHO) classified hematologic malignancies and renamed myloproliferative diseases to myeloproliferative neoplasms.
Rising awareness of molecular abnormalities and cellular pathways involved in the pathogenesis of MPNs is expected to facilitate the development of novel drugs, propels the Myeloproliferative Neoplasms treatment market growth in the near future
Myeloproliferative neoplasm can significantly affect the quality of life of the patient. The complication and treatments as well as the physiological strains of cancer diagnosis can affect the physical and emotional wellbeing of patients. Effects of complication vary from depression, fatigue, pain or depression with suicidal ideation. Moreover, patients can experience few or no symptoms for a longer period of time. MPNs can be cured with proper monitoring and treatment. There has been a major revolution in the management of MPNs by introduction of JAK1 and JAK2 inhibitor and ruxolitinib. Ruxolitinib inhibits these two enzymes in order to manage MPNs. The drug has also been proven as an alternative therapy for the treatment of polycythemia vera. Furthermore, the therapeutic armamentarium for MPN is still inadequate for normalization of life span, reduction in cardiovascular complications, and prevention of hematological progression.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/930
Rising awareness of molecular abnormalities and cellular pathways involved in the pathogenesis of MPNs is expected to increase the number of clinical trials for novel drugs, either alone or in combination with ruxolitinib. Interferon (IFN) is a drug that has proven as an effective alternative for MPNs patients. Better understanding of the mechanism of action for MPNs could lead to better interferon compound and potential drugs. In 2017, MPN research foundation initiated a MPNRF Interferon (IFN) multi-center project which is expected to bring together internationally recognized experts to determine cytokine-driven pathways that affect the path of the MPNs.
Collaborations among the biotech and pharmaceutical companies to identify new drugs for MPNs is expected to accelerate the market growth
Novartis AG and Incyte Corporation are among the key players operating in the Myeloproliferative Neoplasms treatment market. According to the MPN research foundation, demand for improved treatments treatment options is expected to increase among biotech and pharmaceutical companies. Moreover, research and development activities are also expected to propel the market growth. For instance, Incyte Corporation is developing an inhibitor for Janus Kinase (JAK), and is also focusing on discovery, development, and commercialization of proprietary therapeutics across the globe.
Read Press Release: https://www.coherentmarketinsights.com/press-release/myeloproliferative-neoplasm-drugs-market-3663
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Key Developments
- Product Launch/ Approvals
- Mergers, Acquisition & Collaboration
- Pipeline Analysis
- Regulatory Scenario
- PEST Analysis
- Epidemiology
- Market Share Analysis
- Global Myeloproliferative Neoplasm Drugs Market – Impact of Coronavirus (Covid-19) Pandemic
- Supply Side and Demand Side Analysis
- COVID-19 Impact on Overall Healthcare Sector
- COVID-19 Impact on Clinical Trials and Drug Development
- COVID-19 Impact on Cancer Treatment
- Global Myeloproliferative Neoplasm Drugs Market, By Drug Class, 2016–2027 (US$ Mn)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017–2027
- Introduction
- Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
- Segment Trends
- Demethylation Agents
- Introduction
- Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
- Tyrosine kinase Inhibitor
- Introduction
- Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
- Multikinase Inhibitors
- Introduction
- Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
- JAK2 Inhibitor
- Introduction
- Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
- Others
- Introduction
- Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
- Demethylation Agents
- Introduction
- Global Myeloproliferative Neoplasm Drugs Market, By Indication, 2016 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017– 2027
- Segment Trends
- Ph+ Chronic myelogenous leukemia (CML)
- Introduction
- Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
- Ph- Myeloproliferative Neoplasms (MPNs)
- Introduction
- Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
- Myelofibrosis (MF)
- Polycythemia Vera (PV)
- Essential thrombocythemia (ET)
- Ph+ Chronic myelogenous leukemia (CML)
- Introduction
- Global Myeloproliferative Neoplasm Drugs Market, By Distribution Channel, 2016–2027 (US$ Mn)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017– 2027
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
- Hospital Pharmacies
- Introduction
- Global Myeloproliferative Neoplasm Drugs Market, By Region, 2016–2027 (US$ Mn)
- Introduction
- Market Share Analysis, By Country, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, For Countries, 2017–2027
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2020–2027 (US$ Mn)
- Market Size and Forecast, By Indication, 2020–2027 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2020-2027 (US$ Mn)
- Market Size and Forecast, By Country, 2020–2027 (US$ Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2020–2027 (US$ Mn)
- Market Size and Forecast, By Indication, 2020–2027 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2020-2027 (US$ Mn)
- Market Size and Forecast, By Country, 2020–2027 (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2020–2027 (US$ Mn)
- Market Size and Forecast, By Indication, 2020–2027 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2020-2027 (US$ Mn)
- Market Size and Forecast, By Country, 2020–2027 (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2020–2027 (US$ Mn)
- Market Size and Forecast, By Indication, 2020–2027 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2020-2027 (US$ Mn)
- Market Size and Forecast, By Country, 2020–2027 (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2020–2027 (US$ Mn)
- Market Size and Forecast, By Indication, 2020–2027 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2020-2027 (US$ Mn)
- Market Size and Forecast, By Country, 2020–2027 (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2020–2027 (US$ Mn)
- Market Size and Forecast, By Indication, 2020–2027 (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2020-2027 (US$ Mn)
- Market Size and Forecast, By Country/Region, 2020–2027 (US$ Mn)
- South Africa
- Central Africa
- North Africa
- Introduction
- Competitive Landscape
- Company Profiles
- Novartis International AG
- Company Overview
- Clinical Trial Phase Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- PharmaEssentia Corporation
- Company Overview
- Clinical Trial Phase Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Bristol – Myers Squibb
- Company Overview
- Clinical Trial Phase Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Pfizer, Inc.
- Company Overview
- Clinical Trial Phase Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Takeda Pharmaceutical Company Limited
- Company Overview
- Clinical Trial Phase Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Incyte
- Company Overview
- Clinical Trial Phase Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Johnson & Johnson
- Company Overview
- Clinical Trial Phase Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Clinical Trial Phase Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- F. Hoffmann-La Roche AG
- Company Overview
- Clinical Trial Phase Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Gamida Cell
- Company Overview
- Clinical Trial Phase Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Sierra Oncology, Inc.
- Company Overview
- Clinical Trial Phase Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- CTI BioPharma Corp.
- Company Overview
- Clinical Trial Phase Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Imago BioSciences
- Company Overview
- Clinical Trial Phase Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- AbbVie Inc.
- Company Overview
- Clinical Trial Phase Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Constellation Pharmaceuticals
- Company Overview
- Clinical Trial Phase Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Novartis International AG
- Company Profiles
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
Editor Details
-
Company:
- CDN Newswire
